Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
7 Healthcare Stocks That Can Cure a Lackluster Portfolio
04:11pm, Thursday, 19'th Oct 2023
This hasn't been a great year for healthcare stocks. The Dow Jones U.S. Health Care Index is down 4% on the year compared to a 14% gain in the S&P 500 index.
Exclusive: Lilly hires CordenPharma to make diabetes drug Mounjaro's active ingredient -source
01:58pm, Thursday, 19'th Oct 2023
Eli Lilly has hired Switzerland-based contract drugmaker CordenPharma to produce the active ingredient in its diabetes drug Mounjaro, a source familiar with the matter told Reuters on Thursday.
1 Market-Beating Stock to Buy Near Its 52-Week High
09:30am, Thursday, 19'th Oct 2023
Eli Lilly's obesity diabetes medicine Mounjaro continues to show excellent prospects. It should be the biggest growth driver behind the company's sales in the coming years.
4 Ways to Grow $100,000 Into $1 Million for Retirement
09:13am, Thursday, 19'th Oct 2023
Realty Income's total returns deliver. Alphabet is still turning investors into millionaires.
The Next Trillion-Dollar Companies: 3 Stocks to Buy Now
06:51pm, Wednesday, 18'th Oct 2023
The hunt for the next trillion-dollar companies invariably ignites investor excitement. Moreover, the AI-led excitement in equities this year pushed tech stocks to new highs while others reversed the
Eli Lilly is buying another European cancer firm Mablink Bioscience
10:01am, Wednesday, 18'th Oct 2023
Eli Lilly & Co (NYSE: LLY) is buying Mablink Bioscience – a French biotechnology company that focuses primarily on the next-generation, antibody-drug conjugates for cancer. It's the 2nd cancer compa
Eli Lilly (LLY) Registers a Bigger Fall Than the Market: Important Facts to Note
06:47pm, Tuesday, 17'th Oct 2023
Eli Lilly (LLY) reachead $608.31 at the closing of the latest trading day, reflecting a -1.35% change compared to its last close.
Global market for anti-obesity drugs could reach $100B by 2030: Goldman Sachs
05:35pm, Tuesday, 17'th Oct 2023
A report from Goldman Sachs predicts that the total addressable market globally for weight loss drugs could reach $100 billion dollars in sales by 2030. The current market is estimated to be at $6 bil
MedTech Earnings in the Age of Ozempic May Not Be That Bad
02:01pm, Tuesday, 17'th Oct 2023
September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.
Ozempic Sales Are Skyrocketing Faster Than Expected. Here's Why That's Great News for Eli Lilly Stock.
05:50am, Tuesday, 17'th Oct 2023
Novo Nordisk recently raised its full-year 2023 guidance in large part because of greater sales expectations for Ozempic. The same dynamics behind Ozempic's success are also helping Lilly's Mounjaro.
7 Cutting-Edge Stocks That Could Change Humanity as We Know It
06:16pm, Monday, 16'th Oct 2023
They say we're now living in an “age of acceleration” when technological advances are coming at us at breakneck speed. Not long ago, science fiction films and novels depicted a future when we woul
Food and Beverage Stocks Look Appetizing After Ozempic Selloff
04:43pm, Monday, 16'th Oct 2023
It may be time to eat, drink and buy the dip in food and beverage stocks. Shares of Coca-Cola (NYSE: KO ), Pepsi (NASDAQ: PEP ) and several other sugary drink and snack companies have been pummeled la
3 Dividend Growth Stocks You Can Buy and Hold Forever
06:52am, Saturday, 14'th Oct 2023
AbbVie boasts a stellar dividend track record and a resilient business. Eli Lilly's dividend yield might be low, but there's a lot more to the story.
Eli Lilly's (LLY) Mirikizumab Meets Crohn's Disease Study Goals
01:31pm, Friday, 13'th Oct 2023
Based on this data, Eli Lilly (LLY) will initiate regulatory submissions worldwide next year seeking regulatory approval for mirikizumab in Crohn's disease.
What exactly are patients taking new weight-loss drugs eating and what are they avoiding? Bernstein asked them.
11:34am, Friday, 13'th Oct 2023
Bernstein analysts set out to determine that, analyzing online data to better understand changes in eating habits — and to evaluate which food companies may be most affected. They published the resu
